Valuation: Galapagos NV

Capitalization 1.61B 1.89B 1.49B 1.4B 2.61B 176B 2.66B 17.46B 6.83B 84.3B 7.08B 6.93B 300B P/E ratio 2026 *
-10.4x
P/E ratio 2027 * -10.1x
Enterprise value -1.34B -1.58B -1.24B -1.17B -2.18B -147B -2.22B -14.58B -5.7B -70.39B -5.91B -5.79B -251B EV / Sales 2026 *
-7.81x
EV / Sales 2027 * -5.61x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
1 day-2.30%
1 week-3.25%
Current month-8.94%
1 month-13.69%
3 months-16.41%
6 months-19.35%
Current year-14.86%
1 week 23.78
Extreme 23.78
25.62
1 month 23.78
Extreme 23.78
29
Current year 23.78
Extreme 23.78
30.72
1 year 20.7
Extreme 20.7
32.74
3 years 20
Extreme 20
41.92
5 years 20
Extreme 20
69.82
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 13/05/2025
Director of Finance/CFO 43 07/07/2025
Investor Relations Contact - 01/11/2020
Director TitleAgeSince
Director/Board Member 64 22/10/2019
Chairman 68 13/05/2025
Director/Board Member 49 07/10/2024
Change 5d. change 1-year change 3-years change Capi.($)
-2.54%-3.25%+11.72%-32.58% 1.89B
-1.15%+1.07%-4.40%-12.56% 45.62B
-1.20%-0.36%+34.42%+21.49% 34.34B
-0.89%+2.25%+28.92%+21.96% 29.46B
-0.97%-3.42%+14.97%-15.48% 28.09B
+0.22%-2.71%+169.96%+369.02% 19.11B
-1.01%+4.38%+58.47%+191.93% 14.78B
+2.31%-6.43%+2,918.75%+3,811.51% 14.25B
-1.59%-0.97%+65.77%+160.33% 14.09B
-1.28%-2.71%+27.22%+1.31% 13.25B
Average -0.80%-1.58%+332.58%+451.69% 21.49B
Weighted average by Cap. -0.80%-0.84%+229.29%+310.86%

Financials

2026 *2027 *
Net sales 172M 202M 159M 150M 279M 18.77B 285M 1.87B 730M 9.02B 757M 741M 32.12B 162M 191M 150M 142M 264M 17.73B 269M 1.76B 690M 8.52B 716M 700M 30.34B
Net income -244M -286M -225M -212M -395M -26.59B -403M -2.64B -1.03B -12.77B -1.07B -1.05B -45.49B -135M -159M -125M -118M -220M -14.77B -224M -1.47B -575M -7.09B -596M -583M -25.27B
Net Debt -2.95B -3.46B -2.73B -2.57B -4.79B -322B -4.89B -32.03B -12.53B -155B -13B -12.72B -551B -2.52B -2.96B -2.33B -2.2B -4.09B -275B -4.17B -27.35B -10.7B -132B -11.1B -10.86B -471B
Logo Galapagos NV
Galapagos NV is a biotechnology company with operations in Europe, the U.S., and Asia, dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life. Focusing on high unmet medical needs, the company integrates compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class medicines. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, Galapagos NV is committed to challenging the status quo and delivering results for patients, employees, and shareholders. The goal is to meet current medical needs and to anticipate and shape the future of healthcare, ensuring that innovations reach those who need them most.
Employees
704
Date Price Change Volume
13/04/26 23.78 -2.54% 13,936
10/04/26 24.40 +0.08% 44,752
09/04/26 24.38 -0.57% 77,654
08/04/26 24.52 -0.49% 76,205
Trader
Investor
-
Global
-
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
24.40EUR
Average target price
30.15EUR
Spread / Average Target
+23.57%

Quarterly revenue - Rate of surprise